MedTrace Logo

Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients

NCT00358696 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-10-20

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression. We hypothesize that, in patients with maximal virologic suppression on a double class regimen (including two NRTIs and an NNRTI or a PI, boosted with RTV or not), a single drug substitution of didanosine for tenofovir will represent a viable strategy without any negative impact on the virologic efficacy of the regimen.

Conditions

  • HIV
  • HIV Infections

Interventions

DRUG

tenofovir

See Detailed Description.

Sponsors & Collaborators

  • Health Canada

    collaborator OTHER_GOV

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Dr. Brian Conway, MD · University of British Columbia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358696 on ClinicalTrials.gov